Form 8-K · Current report
Danaher Corporation 8-K, filed Jul 21, 2026
- Filed
- CIK
- 0000313616
- Accession no.
- 0000313616-26-000163
Summary
Danaher Corporation reported second quarter 2026 net earnings of $870 million, or $1.23 per diluted share, on revenue of $6.3 billion, up 5.5% year-over-year, with adjusted diluted EPS of $1.94. The company raised its full-year 2026 adjusted diluted EPS guidance to $8.45–$8.60, citing stronger-than-expected quarterly performance and the earlier-than-anticipated completion of the Masimo acquisition.
Key points
- Danaher reported second quarter 2026 net earnings of $870 million, or $1.23 per diluted share, up 60% year-over-year.
- Revenue rose 5.5% to $6.3 billion; non-GAAP adjusted diluted EPS grew 8.0% to $1.94, with non-GAAP core revenue up 3.0%.
- The company raised full-year 2026 adjusted diluted EPS guidance to $8.45–$8.60 from $8.35–$8.55 and expects full-year core revenue growth of 3.0%–4.0%.
- CEO Rainer M. Blair said the Life Sciences businesses had their strongest quarter in several years and bioprocessing orders grew mid-teens, while customer project timing weighed on bioprocessing revenue.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION On July 21, 2026, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the quarter ended June 26, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.